Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Illumina launches three new Sequencing Systems and New Diagnostic Plans: Noninvasive Prenatal Testing and Oncology Markets

Reporter: Aviva Lev-Ari, PhD, RN

Illumina Launches Four New Systems; Provides Financial, Dx Update at JP Morgan

Jan 12, 2015 | Ed Winnick

SAN FRANCISCO (GenomeWeb) – Illumina today announced the launch of three new sequencing systems and provided an update on its diagnostic plans in the noninvasive prenatal testing and oncology markets.

Speaking at the JP Morgan Healthcare Conference, CEO Jay Flatley preannounced fourth quarter revenues of $512 million, as well as $1.86 billion in FY 2015 revenues, representing 31 percent year-over-year growth. He said the firm expects revenue growth of 20 percent in FY 2015.

He also unveiled the HiSeq X Five System, the HiSeq 3000 and 4000 Systems, and the NextSeq 550 System, an NGS system enabled for array scanning.

The HiSeq X Five is a scaled down version of the X Ten, which was launched at last year’s JP Morgan conference. It consists of five individual HiSeq X instruments, enabling more “capital-constrained” customers to adopt high-throughput whole-genome sequencing with a lower capital investment, Flatley said. The X Five provides the throughput to sequence more than 9,000 genomes a year, he noted, and will cost $6 million per system. Customers will be able to produce a genome for around $1,400 with the system, which will launch in the second quarter of 2015.

Flatley said that the firm sold far more X Ten systems in 2014 than it had initially anticipated. In total, he said the firm signed up 18 customers and sold 201 X Ten units during the year, including 37 sold in the fourth quarter.

The HiSeq 3000 and 4000 systems build on the capabilities of the HiSeq 2500 System and leverage the patterned flow cell technology developed for the HiSeq X Ten System.

SOURCE

https://www.genomeweb.com/business-news/illumina-launches-four-new-systems-provides-financial-dx-update-jp-morgan